A feedback mechanism between PLD and deadenylase PARN for the shortening of eukaryotic poly(A) mRNA tails that is deregulated in cancer cells by Miller, Taylor E. & Gomez-Cambronero, Julian
A feedback mechanism between
PLD and deadenylase PARN for the
shortening of eukaryotic poly(A) mRNA
tails that is deregulated in cancer cells
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Miller, Taylor E., and Julian Gomez-Cambronero. 2017. “A feedback
mechanism between PLD and deadenylase PARN for the shortening
of eukaryotic poly(A) mRNA tails that is deregulated in cancer
cells.” Biology Open 6 (2): 176-186. doi:10.1242/bio.021261. http://
dx.doi.org/10.1242/bio.021261.
Published Version doi:10.1242/bio.021261
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:32072039
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
RESEARCH ARTICLE
A feedback mechanism between PLD and deadenylase PARN for
the shortening of eukaryotic poly(A)mRNA tails that is deregulated
in cancer cells
Taylor E. Miller2 and Julian Gomez-Cambronero1,2,*
ABSTRACT
The removal of mRNA transcript poly(A) tails by 3′→5′ exonucleases
is the rate-limiting step in mRNA decay in eukaryotes. Known cellular
deadenylases are the CCR4-NOT and PAN complexes, and poly(A)-
specific ribonuclease (PARN). The physiological roles and regulation
for PARN is beginning to be elucidated. Since phospholipase D
(PLD2 isoform) gene expression is upregulated in breast cancer cells
and PARN is downregulated, we examined whether a signaling
connection existed between these two enzymes. Silencing PARN
with siRNA led to an increase in PLD2 protein, whereas
overexpression of PARN had the opposite effect. Overexpression of
PLD2, however, led to an increase in PARN expression. Thus, PARN
downregulates PLD2 whereas PLD2 upregulates PARN. Co-
expression of both PARN and PLD2 mimicked this pattern in non-
cancerous cells (COS-7 fibroblasts) but, surprisingly, not in breast
cancer MCF-7 cells, where PARN switches from inhibition to
activation of PLD2 gene and protein expression. Between 30 and
300 nM phosphatidic acid (PA), the product of PLD enzymatic
reaction, added exogenously to culture cells had a stabilizing role of
both PARN and PLD2 mRNA decay. Lastly, by immunofluorescence
microscopy, we observed an intracellular co-localization of PA-loaded
vesicles (0.1-1 nm) and PARN. In summary, we report for the first time
the involvement of a phospholipase (PLD2) and PA in mediating
PARN-induced eukaryotic mRNA decay and the crosstalk between
the two enzymes that is deregulated in breast cancer cells.
KEY WORDS: Mammalian cells, Cell signaling, Gene expression,
Breast cancer, MRNA decay, Ribonuclease, Deadenylase
INTRODUCTION
The shortening of eukaryotic poly (A) mRNA tails is a key way to
repress mRNA translation and to induce transcript turnover.
Deadenylation is a principal strategy employed by cells to control
mRNA stability and gene expression involved in basic cellular
functions, such as development and cell differentiation, as well as in
pathological conditions, such as chronic inflammation, cancer and
an abnormal DNA damage response (Mazan-Mamczarz et al.,
2003; Zhang et al., 2010, 2015; Jalkanen et al., 2014). Cytoplasmic
removal of poly(A) tails of mRNA transcripts by 3′→5′
exonucleases (deadenylases) is considered the rate-limiting step
for controlled mRNA decay (Wilson and Treisman, 1988a; Shyu
et al., 1991; Mitchell and Tollervey, 2000; Funakoshi et al., 2007;
Nousch et al., 2013; Wolf and Passmore, 2014). Two well-
documented cell deadenylases are the CCR4-NOT transcriptional
regulatory complex and the PAN complex. By contrast, a third
deadenylase, poly(A)-specific ribonuclease (PARN), which is a
member of the RNase D exonuclease family and also degrades poly
(A) from the 3′ end (Mian, 1997; Moser et al., 1997; Körner et al.,
1998), is lesser known in terms of its own specific functional roles
and regulation in vivo.
PARN is a divalent metal (Mg2+) ion-dependent, poly(A)-
specific, oligomeric, processive, and 5′ cap-interacting 3′
exonuclease (Martinez et al., 2000). The main action of PARN in
mRNA decay is by exonucleolytic cleavage of poly(A) tails to
adenosine monophosphate (AMP) and continued mRNA
degradation in the 3′ to 5′ direction (Martinez et al., 2000).
PARN targets a group of transcripts that code for cell migration and
adhesion factors (Lee et al., 2012), and is implicated in the targeted
regulation of protein mRNAs including but not limited to those
involved in p53, FAK and ERK/MAPK signaling, Fcγ receptor-
mediated phagocytosis and BRCA1 DNA damage response
(Devany et al., 2013). Additionally, PARN physically associates
with Ago2 in the RNA-inducing silencing complex (RISC) (Zhang
et al., 2015), and degrades the oncogenic microRNA, miR-21-CA,
allowing PTEN and p53 to function properly as tumor suppressors
(Buiting et al., 1999; Copeland andWormington, 2001; Boele et al.,
2014). Different cancers display different levels of PARN
expression, and PARN can directly regulate the stability of
transcripts for c-myc, c-fos, c-jun and others in the p53 and
BRCA pathways. The deadenylase activity of PARN ensures low
levels of these mRNAs under normal conditions (Moraes et al.,
2006; Cevher et al., 2010; Maragozidis et al., 2012; Devany et al.,
2013; Zhang et al., 2015). Recently, PARN deficiency has been
shown to be involved in telomere disease and cause dyskeratosis
congenital, while telomere shortening and familial pulmonary
fibroses are linked to mutations in PARN (Mason and Bessler,
2015; Stuart et al., 2015; Tummala et al., 2015).
Phospholipase D (PLD) is a membrane protein important for the
structural integrity of cellular membranes and also for its role in
cellular signaling through protein-protein interactions or through the
product of enzymatic reaction, phosphatidic acid (PA) (Gomez-
Cambronero, 2014). There are several isoforms of PLD, but the
most studied have been PLD1 and PLD2. The basic action of PLD is
to hydrolyze phosphatidylcholine (PC) into its lipid second
messenger, PA, and also choline (Wang et al., 1994). PLD and
PA regulate cell adhesion of immune cells to collagen, whichReceived 14 August 2016; Accepted 6 December 2016
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involves mechanistic control that coincides with the timing of PLD
activity (Zhao et al., 2007; Speranza et al., 2014). PLD2 is
implicated in a wide variety of disease states. PLD2 overexpression
is connected to breast cancer cell growth, proliferation, and
metastasis (Henkels et al., 2013) through interactions between
PLD2 and the mammalian target of rapamycin (mTOR) pathway,
stabilization of mutant p53 and promotion of factors involved in
cancer cell proliferation (Gomez-Cambronero, 2014). The PA
produced in PLD hydrolysis reactions is also highly mitogenic and
is involved in chemotaxis and cell growth (Gomez-Cambronero,
2014).
Elevated PLD2 expression is known to be a cancer survival signal
(Foster, 2004; Rodrik et al., 2005; Hui et al., 2006; Shi et al., 2007;
Hatton et al., 2015), but how PLD2 regulates other signaling
proteins or how it is regulated at the level of gene expression is not
well characterized. Our study showed that the shortening of
eukaryotic poly(A) mRNA tails by the deadenylase PARN is
mediated by PLD2 and PA.We also present evidence that PLD2/PA
regulates PARN expression and that PARN also in turn regulates
PLD2 transcript levels in a negative feedback loop that is
deregulated in cancer cells.
RESULTS
Differential expression of PARN and PLD2 in breast cancer
cells compared to non-cancerous cells
A molecular connection between poly(A) deadenylases and PLD
has not been investigated to date. Using the Finak Breast dataset
from the ONCOMINE cancer microarray database (Finak et al.,
2008), we determined that PARN was downregulated in invasive
breast carcinoma compared to adjacent non-cancerous breast
stroma (Fig. 1A), while gene expression of PLD2 was
significantly upregulated in the same dataset (Fig. 1B). These
data suggest that PARN downregulation allowed activation of
post-transcriptional events normally kept under its control, which
could contribute to cancer development and progression in which
PLD2 has already been implicated (Kang et al., 2009; Park and
Min do, 2011; Henkels et al., 2013; Kang et al., 2015). We
determined the endogenous gene expression of both PARN and
PLD2 in COS-7 fibroblasts, used as a non-cancerous ‘normal’ cell
line, as well as in the breast cancer cell line MCF-7. As shown in
Fig. 1C,D, MCF-7 cells have both significantly lower gene
expression of PARN compared to COS-7 and significantly higher
gene expression of PLD2, which also reflect the results shown in
Fig. 1A,B. The fact that MCF-7 cells had more PLD2 expression
than non-cancerous cells was in accordance to previous studies
(Fite and Gomez-Cambronero, 2016). However, the fact that
MCF-7 cells had less PARN expression than non-cancerous cells
was not expected, and as such, we pursued this interesting and
potentially novel point further.
PARN negatively regulates PLD2 expression in non-
cancerous cells and PLD2 positively regulates PARN
When PARN was silenced in the non-cancerous COS-7 cell line
(Fig. 2A-E), PLD2 protein increased above the mock and negative
siRNA-transfected cells (Fig. 2A,C), while PARN protein
decreased (Fig. 2A,B). Fig. 2D is the positive control for these
experiments, which shows effective silencing of the PARN gene.
Interestingly, while PLD2 protein expression increased with PARN
silencing, PLD2 gene expression did not change (Fig. 2E), possibly
due to faster degradation of a pool of PLD2 mRNA in these
non-cancerous cells. In PARN-silenced cancerous MCF-7 cells
(Fig. 2F-J), PLD2 protein increased above the mock- and negative
control-transfected cells (Fig. 2F,H), while PARN protein (Fig. 2F,
G) and gene expression (Fig. 2I) were both silenced. These results
indicate that PARN has a strong negative regulatory effect on
cellular PLD2 levels.
Role of the catalytic activities of PLD and PARN
We next investigated if the catalytic activity of PARN affected PLD2
gene expression. Using a PARN deadenylase-inactive mutant,
PARN-H377A, we observed that the ectopic expression of the
inactive mutant PARN also decreased expression of PLD2 (Fig. 3A),
which was similar to that of wild-type PARN (Fig. 2). This result
means that PARN overexpression decreased PLD2 gene expression
independent of its deadenylase activity. However, since the PARN-
H377A mutant still contains two intact RNA-binding domains,
PARN binding to PLD2 mRNA could be destabilized, which could
prevent translation of PLD2. Interestingly, when we performed the
opposite experiment, one that induced overexpression of PLD2, and
then tested the resulting effect on PARN gene expression (Fig. 3B),
we observed that the positive effect on PARN gene expression was
reversed by overexpression of the lipase-inactive PLDmutant. Thus,
the catalytic activity of PARN does not seem to be necessary for
PLD2 regulation, but the catalytic activity of PLD is necessary for
PARN regulation.
Differential effects of PARN+PLD2 co-expression in non-
cancerous cells versus breast cancer cells
Since a robust signaling interaction between PARN and PLD2 seems
to exist in non-cancerous and cancerous cells, we next transfected
both types of cells with a combination of expression plasmids coding
for both the PARN and PLD2 proteins. Co-expression of PARN
Fig. 1. PARN is differentially expressed in breast cancer versus non-
cancerous tissue/cells. (A,B) Analysis of PARN (A) and PLD2 (B) expression
in human breast cancer versus normal adjacent tissue using microarray data
from the Finak Breast Dataset (Finak et al., 2008). See Materials and Methods
for details. (C,D) Gene expression of PARN (C) or PLD2 (D) in COS-7 and
MCF-7 cell lines. Quantitative RT-PCR results in C,D are normalized to the
averaged results of the three housekeeping genes used: GAPDH, Actin, and
TBP (TATA-binding protein). Data presented as bars are means+s.e.m.
Experiments were performed in technical triplicates (for qRT-PCR assays) for
n=5 independent experiments. The difference between means was assessed
by single-factor ANOVA.) *P<0.05, significant increase between samples and
controls; #P<0.05, significant decrease between samples and controls.
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+PLD2 in COS-7 cells led to an overabundance of PARN protein
expression with a concomitant abrogation in PLD2 protein
expression (Fig. 3C). Surprisingly, in the MCF-7 breast cancer
cells, both PARN and PLD2 protein co-overexpression augmented
the expression of each of these proteins in parallel (Fig. 3D). The
results of RT-qPCR assays to measure gene expression are shown for
PLD2 in Fig. 3E,F and for PARN in Fig. 3G,H, which also reinforce
the protein expression results shown in Fig. 3C,D, in that the
expression of PLD2 was at its highest in MCF-7 cancer cells when
co-expressed with PARN. Since PLD2 levels are naturally high in
cancer cells (Hui et al., 2006; Zheng et al., 2006; Shi et al., 2007), our
results indicate that either PARN is deregulated in cancer cells, not
allowing inhibition of PLD2 expression, or that PLD2 activity
contributes to increased mRNA stabilization, or both. Such
synergism would be advantageous for a cancer cell, as PLD is
implicated in cell invasion and cancer metastasis (Knoepp et al.,
2008; Chen et al., 2012; Henkels et al., 2013)
Phosphatidic acid increased both PARN and PLD2 protein
and gene expression
As PLD had a positive effect on PARN expression (Fig. 3C-H) that
was negated by a catalytically inactive form of PLD (Fig. 3B), we
investigated what effect PA (the product of PLD reaction) might
have on PARN. PA is known to be a strong mitogen and regulator
of gene transcription (Yoon et al., 2015). COS-7 cells were
incubated with increasing concentrations of 1,2-dioleoyl-sn-3-
phosphate (dioleolyl-PA) for either 20 min or 4 h. As shown in
Fig. 4A,B, both PLD2 and PARN protein expression increased
concomitantly with PA concentration. Quantification of protein
bands are shown in Fig. 4C-F. Both PLD2 and PARN protein
expression increased during this 4 h incubation up to a peak at
∼100 nM dioleolyl-PA followed by a decrease at higher
concentrations of dioleolyl-PA (Fig. 4D,F). This effect was
shifted to higher concentrations of dioleolyl-PA during a shorter
incubation time (20 min) (Fig. 4C,E). These results indicate that
Fig. 2. Silencing of PARN increased PLD2 protein expression. Cells were treated with transfection reagents only (Mock) or silenced with siRNA-negative
control (Neg.) or with siRNA for PARN as indicated. Four days post-transfection, lysates were used for protein and gene expression analyses. (A-C) Protein
expression for COS-7 cells and (F-H) for MCF-7 cells. Western blots are presented in A and F and the densitometry of PARN and PLD2 bands are shown in
COS-7 cells (B-C) and MCF-7 cells (G-H). Actin was used as the equal protein loading control. (D,E) Gene expression for COS-7 cells and (I,J) for MCF-7
cells measured by RT-qPCR using the three housekeeping genes as indicated in the Fig. 1 legend. Data presented as bars are means+s.e.m. The difference
between means was assessed by single-factor ANOVA. *P<0.05, significant increase between samples and controls; ##P<0.01, significant decrease
between samples and controls.
178
RESEARCH ARTICLE Biology Open (2017) 6, 176-186 doi:10.1242/bio.021261
B
io
lo
g
y
O
p
en
there is a concentration- and time-dependent threshold to which the
cells produce more protein in response to PA that could be reversed.
Phosphatidic acid stabilized mRNA decay and counteracted
an enhanced mRNA degradation rate caused by PARN
overexpression
PARN is one of the main deadenylases that regulates the amount of
mRNA at a given time in the cell, thus having a profound effect on
mRNA decay (Utter et al., 2011). We have determined that dioleolyl-
PA treatment in the absence and presence of overexpressed PARN
has positive effects on PARN mRNA levels (Fig. 5A), while PARN
negated this positive effect of dioleolyl-PA (Fig. 5B).We next studied
mRNA decay. Fig. 5C,D show that actinomycin treatment of cells
arrested RNA transcription as a function of time. As expected, PARN
mRNA decay was observed in Fig. 5C, while PLD2 mRNA decay
was observed in Fig. 5D (dashed red lines for both genes). Not
Fig. 3. PLD2 and PARN overexpression affects PARN
and PLD2 protein and gene expression. (A) PARN
overexpression of catalytically active or deadenylase-
inactive (PARN-H377A) plasmids and their effect on PLD2
gene expression in COS-7 cells. (B) PLD2 overexpression
of catalytically active or lipase-inactive (PLD2-K758R)
plasmids and their effect of PARN gene expression in
COS-7 cells. (C-H) Co-expression of PARN and PLD2 in
two different cell lines: COS-7 (C,E,G) and MCF-7 (D,F,H).
(C,D) Protein expression by western blot (actin was used as
a gel loading control). Cells were left untransfected (mock)
or transfected with PLD2 or PARN plasmids individually or
in combination (PLD2+PARN). (E,F) PLD2 gene expression
and (G,H) PARN gene expression, in either case detected
by RT-qPCR. Data presented as bars are means+s.e.m.
The difference between means was assessed by single-
factor ANOVA. *P<0.05, **P<0.01, ***P<0.005, significant
increase between samples and controls; #P<0.05,
significant decrease between samples and controls.
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surprisingly, overexpression of PARN accelerated PLD2 mRNA
decay (Fig. 5D, green lines). However, this was reversed by the
addition of dioleyl-PA to the culture media (Fig. 5D, blue and black
lines). This mRNA decay protection afforded by dioleoy-PAwas also
observed in samples that overexpressed PARN (Fig. 5C, blue lines).
These data support a PLD-PA function that stabilized mRNA and
protected against degradation as a way of counteracting the enhanced
mRNA degradation rate caused by PARN overexpression, which
could play an even major role in cancerous cells.
Exogenous phosphatidic acid added to cell cultures slightly
enhances PARN deadenylase activity, as measured in vitro
We next investigated if PA affects the deadenylase activity of PARN.
To accomplish this goal, we set up a robust and reliable in vitro
enzymatic PARN deadenylase assay, validated in Fig. 6A-C. In
Fig. 6A, [32P]-γATP-radiolabeled A15 RNA substrate was
deadenylated by recombinant PARN with respect to the A15-only
control. Deadenylation was evidenced by an increased mobility of
radiolabeled and degraded products (the smeared product) versus the
input A15 negative control alone. Fig. 6B shows that recombinant,
purified PARN protein but not recombinant, purified PAN2 protein
(another closely related deadenylase, as stated in the Introduction)
deadenylated the A15 substrate. Fig. 6C shows a Coomassie-stained
gel that indicates the high purity of the recombinant, purified proteins
used. PARN deadenylase activity was effectively silenced in cells
with siPARN RNA (Fig. 6D) but not with siPAN2 RNA. This
indicates that in our assay conditions, PAN2 did not contribute to the
deadenylase activity found in cell lysates.
A further control for these activity experiments is shown in Fig. 6E,
whereby PARN activity in lysates from cells overexpressing wild-
type PARN increased in a concentration-dependent manner when
compared to overexpression of the deadelynase-inactive mutant
PARN-H377A. Dioleoy-PA at 30 nM slightly affected deadenylase
activity of PARN in PLD2-overexpressing cells (Fig. 6F), although
the increase in PARNmassmay end up cancelling that effect. Further,
PLD activity (Fig. 6G) was enhanced by dioleoyl-PA but the
combination of dioleoyl-PA+ PARN overexpression proved once
again to negatively impact PLD activity (as in Fig. 5B for gene
expression). Taken together, these data indicate that PARN
overexpression negatively affects PLD lipase activity, and PLD2
positively affects PARN expression and activity.
PARN localizes to PA-containing vesicles
The level of PLD2 and PARN interregulation we have documented
suggests that these two proteins interact with one another and could
potentially be in close spatial proximity. To test this hypothesis, we
utilized a fluorescently-tagged form of PA, green fluorescent 1-
oleoyl-2-{6-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]hexanoyl}-
sn-glycero-3-phosphate (NBD-PA) that could be easily incubated
with cultured cells. Subsequent immunofluorescence microscopy of
such cell samples could reveal the potential co-localization of
fluorescently-labeled PARN with the NBD-tagged PA. In our
experimental design, PARN was stained red in these samples using
anti-PARN-TRITC IgG antibody labeling, NBD-PAwas green and
DAPI-stained nuclei were blue. As shown in Fig. 7A-F, the green
NBD-PA localized diffusely throughout the cytoplasm of the COS-
7 cells but also localized very strongly in vesicles near the nucleus.
PARN was observed inside the nucleus, particularly in the nucleoli,
and also in the NBD-PA-containing vesicles (as seen by the strong
yellow signal in the merged images).
Quantification of the co-localized PARN+NBD-PA signals
(Fig. 6G) indicates that PARN co-localized with PA to
large vesicles (>0.5 mm) to a very large extent (close to 90%)
and to punctate vesicles (<0.5 mm) (close to 75%). We have
observed a similar localization pattern for PA in cells in a previous
study that focused on the role of PA as an intracellular transport
conveyor for the epidermal growth factor receptor (EGFR)
(Henkels et al., 2016). We believe that trafficking of
intracellular PA assists in mediating the effects of PARN on
PLD2, especially in regards to PARN deadenylation activity and
PLD2 mRNA decay.
A model of regulation between PLD2/PA and PARN
Amodel representing the proposed regulation we have characterized
between PLD2/PA and PARN is presented in Fig. 8. The results of
our novel study indicate that eukaryotic mRNA decay was regulated
by PARN and the activation and synthesis of PARN was enhanced
by phosphatidic acid (PA), the hydrolysis product of phospholipase
D2 (PLD2). When PLD2/PA levels were increased in non-
cancerous cells, like COS-7, this caused an increase in PARN
gene and protein expression, as well as an increase in its
deadenylase activity. This overall elevation in PARN levels in the
cell then decreased PLD2 expression to basal levels. A negative
feedback mechanism exists in cells, whereby PLD2 overexpression
and PA production positively affected PARN gene and protein
expression, while PARN overexpression negatively affected PLD2
gene and protein expression. The large negative feedback of PARN
on PLD expression was attenuated in cancer cells, perhaps due to the
Fig. 4. Exogenous dioleoyl-PA increases PARN protein expression. (A,B)
Western blots showing endogenous levels of PARN, PLD2 and actin protein in
COS-7 cells in response to 20 min (A) or 4 h (B) incubation with increasing
concentrations of dioleoyl-PA as indicated. (C-F) Densitometry analyses of
data shown in A,B. (C,D) Results of densitometry of PARN bands from western
blots similar to the ones shown in A,B for 20 min (C) and 4 h (D). (E,F) Results
of densitometry of PLD2 bands from western blots similar to the ones shown in
A,B for 20 min (E) and 4 h (F). Data are presented as means+s.e.m. *P<0.05
by single-factor ANOVA.
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effect of an as-yet-unidentified regulator (shown in Fig. 8), which
supports the significant role of PLD in this disease, and relates to the
relative higher level of cell invasiveness and metastatic potential
found in breast cancers.
DISCUSSION
This work identifies that the phospholipid signaling enzyme PLD2
and its catalytic product, PA, are a novel route for modulating
PARN-mediated mRNA decay in higher eukaryotes. We report that
a possible inter-regulatory relationship exists, whereby PLD2
affected PARN gene and protein expression, as well as activity and
vice versa. This mechanism appears to be modulated differently in
non-cancer versus cancer cells. The degradation of many mRNAs
is initiated by poly(A) tail shortening and can be accomplished by
(1) the PAN complex system, (2) the CCR4/NOT complex
(Basquin et al., 2012) and (3) by the herein-reported PA/PLD2-
regulated PARN. The results shown here support an important role
for PA and PLD2 in PARN mRNA decay and deadenylation of
mRNA transcripts, independently of the PAN and CCR4/NOT
complexes.
The relationship between phospholipases and RNases is
interwoven in terms of cellular location and function. Previous
studies have linked phospholipase C (PLC) to RNase activity, which
can be used as a basis for the possibility of other phospholipases
being involved in RNase activities, such as PLD2/PA-regulated
PARN. It has been previously determined that PLD and
ribonucleases co-localize in the vacuoles of plants (Matile, 1968).
It is already known that PARN exists both in the cytoplasm and
nucleus, whereas PLD2 has been shown to be in the cytoplasm,
while PA, the important secondary messenger product of PLD2, can
be found throughout the cell to exert a variety of functions in cell
signaling. (Zini et al., 1989; Hondal et al., 1997; Kravchuk et al.,
2001). Taken together, the research on PLC and understanding the
subcellular localization of PLD2, PA and PARN, support the notion
that these molecules have ample opportunity and probability of
direct and/or indirect interaction.
What purpose does the dual feedback in cancer cells serve? By
using normal and breast cancer cell lines that were mock-treated or
that overexpressed PARN and/or PLD2, we defined the
relationship between PARN and PLD2. First and foremost,
cancer cell lines have increased levels of PLD2 and therefore
higher levels of PA production (Foster, 2009; Foster et al., 2014).
The product of PLD hydrolysis of membrane PC is almost
exclusively monounsaturated PA (e.g. dioleoyl-PA), and as such
we have used exogenously added dioleolyl-PA in our experiments.
Our exogenously added PA stabilized both PARN and PLD2
mRNA degradation through the partial or total inhibition of
mRNA decay. We believe that a negative feedback mechanism
exists in cells, whereby PLD2 overexpression positively affected
PARN gene and protein expression, while PARN overexpression
negatively affected PLD gene and protein expression. This
negative feedback mechanism between PARN and PLD2 was
diminished in our breast cancer cell line, MCF-7, possibly due to
an as-yet-unidentified regulator or pathway that leads to the
attenuation of the large negative feedback of PARN on PLD2
expression, further supporting the significant role of PLD in this
disease, as relates to the relative level of cell invasiveness and
metastatic potential. Cancer cells having low levels of RNase
could potentially maintain a more active pool of RNA and
facilitate overexpression of proteins like PLD2 that are highly
relevant to cell migration and metastasis.
Regarding the mechanism of how PA inhibited PARN-induced
mRNA decay, we considered the previous work on polycationic
aminoglycoside antibiotics (Hermann and Westhof, 1998;
Woegerbauer et al., 2000). These antibiotics inhibit PARN activity,
although the possibility of steric hindrance must also be considered.
Our data on the inhibitory effect of PA on PARN takes into account a
potential direct effect on the enzyme itself, not on RNA, as PA is
negatively charged. It is possible that the mechanism of the inhibition
of PARN-induced mRNA decay by anionic PA is that PA displaces
catalytically essential divalent metal ions in the active site of PARN
that diminishes the processivity of the deadenylation reaction. PARN
Fig. 5. Effect of dioleolyl-PA treatment on ectopic expression of
PARN and mRNA decay. (A,B) COS-7 cells were transfected with
PARN or left untrasnfected (Mock) for 48 h. On the day of the
experiment aliquot samples were treated with 300 nM dioleoyl-PA in
culture for 20 min (white bars) or for 4 h (black bars). Cells were
processed for the measurement of gene expression by RT-qPCR for
either PARN (A) or PLD2 (B). Data in A,B presented as bars
are means+s.e.m. The difference between means was assessed by
single-factor ANOVA. *P<0.05, significant increase between
samples and controls; #P<0.05, significant decrease between
samples and controls. (C,D) mRNA decay study. COS-7 cells were
overexpressed with PARN or left untransfected (Mock) for 48 h and
incubated with 50 nM actinomycin D on the day of the experiment,
for the indicated lengths of time, in the absence or presence of
300 nM dioleoyl-PA. RNA was extracted and then used for qRT-
PCR analyses. Relative gene expression was used to determine the
levels of mRNA decay for PARN (C) and PLD2 (D) and are
expressed in the graphs in terms of mean percentage of control
(normalized as 100)±s.e.m. *P<0.05 by single-factor ANOVA.
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was initially identified as a Mg2+-dependent exonuclease (Astrom
et al., 1991; Körner and Wahle, 1997; Copeland and Wormington,
2001), and our findings are in agreement with reports on DNaseI
(Woegerbauer et al., 2000) and PLC (Burch et al., 1986).
In conclusion, we report here a regulatory relationship
between PARN and PLD2/PA, which constitutes a new and
possibly essential component in post-transcriptional regulation in
higher eukaryotes, as well as in disease states such as cancer.
Further investigation is needed into determining how and why
the interaction between these two proteins becomes dysregulated
in breast cancer to develop methods for re-establishing
normal interaction and remedying or preventing the cancerous
pathology.
MATERIALS AND METHODS
Materials
Rabbit PLD2 (N-term) (Abgent AP14669a, San Diego, CA), rabbit Pierce
PARN (Thermo Scientific PA5-30252, Pittsburgh, PA), rabbit beta-actin
(Cell Signaling 4970S), and HRP-linked rabbit IgG (Cell Signaling 7074S)
antibodies were used for western blots. For immunofluorescent microscopy,
goat PARN (N-12) (sc-47618) and donkey anti-goat IgG-R (sc-2094) were
purchased from Santa Cruz Biotechnology (Dallas, TX). Antibodies were
validated by the manufacturer. 1,2-dioleoyl-sn-3-phosphate (dioleolyl-PA;
840875) and green fluorescent 1-oleoyl-2-(6-[(7-nitro-2-1,3-
benzoxadiazol-4-yl)amino]hexanoyl)-sn-glycero-3-phosphate (NBD-PA;
810175) were purchased from Avanti Polar Lipids (Alabaster, AL).
Transit 2020 transfection reagent was from Mirus Bio (Madison, WI).
ECL western blotting reagents were from GE Healthcare (Piscataway, NJ).
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Fig. 6. Effect of PLD or dioleoyl-PA on
PARN deadenylation activity.
(A,B) Validation study for in vitro PARN
deadenylase activity. (A) Radiolabeled A15
RNA substrate was deadenylated by
recombinant PARN with respect to the
A15-only control. Deadenylation is evidenced
by a greater mobility of radiolabeled spots
and the appearance of smears versus the
negative control of A15 alone.
(B) Recombinant PARN, but not recombinant
PAN2 is able to deadenylate A15.
(C) Coomassie-stained gel indicating the high
purity of the recombinant, purified proteins
used. (D) PARN deadenylase activity as
measured in lysates from COS-7 cells that
were silenced with 150 ng of either control
RNA (SiNeg), siPARN RNA or siPAN2 RNA.
(E) PARN activity in overexpressing cells was
concentration dependent from cell lysates in
comparison with the deadelynase-inactive
mutant PARN-H377A. (F) PARN activity of
lysates prepared from COS-7 cells
overexpressing PLD2 incubated with or
without dioleolyl-PA. (G) PLD activity of
COS-7 cells overexpressing PLD2 alone
(control) or co-overexpressed with PARN-WT
or the PARN mutant. Data are presented as
means+s.e.m. The difference between
means was assessed by single-factor
ANOVA. *P<0.05, significant increase
between samples and controls; #P<0.05,
significant decrease between samples and
controls.
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qPCR reagents and enzymes were from Fisher Scientific/Life Technologies
(Pittsburgh, PA). Plasmid DNAs used herein were as follows: pcDNA3.1-
myc-PLD2-WT and pcDNA3.10-myc-PLD2-K758R were previously
designed in our lab, pCMV6-myc-DDK-PARN-WT was from Origene
(RC207220, Rockville, MD) and this plasmid was the basis for site-directed
mutagenesis to generate PARN-H377A. Ambion single siRNA were
purchased from ThermoFisher Scientific and were as follows: 5 nM
PARN siRNA (AM16708 ID#: 11661), 5 nM PAN2 siRNA (|AM16708A
ID#: 105177), and 50 µM Negative Control siRNA (AM4611). Pooled
siRNAwere purchased from Santa Cruz Biotechnology and were as follows:
10 µM PARN siRNA (sc-61297) and 10 µM control siRNA-A (sc-37007).
Recombinant purified PARN (TP307220) and PAN2 (TP300573) were
purchased from Origene.
Cells and cell culture
COS-7 and MCF-7 cells were obtained from ATCC (Manassas, VA, USA).
The repository has indicated that the cell lines were recently authenticated
and tested negative for contamination. DMEM was from HyClone and
supplemented with 10% (v/v) FBS. Cells were maintained at 37°C in an
incubator with a humidified atmosphere of 5% CO2. COS7 andMCF-7 cells
Fig. 7. Co-localization of PARN with NBD-PA. COS-7 s were incubated for
30 min in 30 nM fluorescent PA (NBD-PA) and were then used for
immunofluorescence microscopy using TRITC-conjugated α-PARN IgG
antibodies. (A-F) Sextuplicate fields. Localization of the NBD-PA is in green
(excitation=490 nm; emission=525 nm, using a FITC filter) and localization of
PARN is in red (excitation=557 nm; emission=576 nm, using a TRITC filter).
Nuclei were stained blue with DAPI and the images merged. (G) PA/PARN co-
localization, represented by the presence of yellow (550 nm)
immunofluorescence, as indicated in Methods, in large vesicles (>0.5 mm);
punctae (<0.5 mm) or diffuse distribution. This classification of vesicles is in
accordancewith a previous publication from our lab (Henkels et al., 2016). The
dashed line marks the threshold for ratios of least 70% of maximum values.
Each bar is the average of the six images shown plus other three fields not
shown, for a total of n=18. Data are presented as means+s.e.m.
Fig. 8. Proposed model for the interactions of PARN with PLD2 in non-
cancerous versus cancerous cells. (A) In non-cancerous cells, where PARN
expression surpasses PLD2 expression, a positive and a negative feedback
mechanism exists, whereby PLD2 and PA production initially upregulates
PARN gene and protein expression. This PARN protein then decreases PLD2
expression by degrading PLD2 mRNA bringing PLD2 levels back to a normal
level. (B) Working model for the deregulation between PARN and PLD2 in
cancerous cells, where PLD2 expression surpasses PARN expression. As in
non-cancerous cells, PLD upregulates PARN. However, PARN can not
downregulate PLD. Either degradation of mRNA is compromised by an
stabilizing effect of PA or a positive regulator exists between PARN and PLD
protein translation (yet to be established), leads to higher PLD2 protein
expression, which mediates the indicated functionality of these cells.
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were cultured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% (v/v) fetal bovine serum (FBS).
ONCOMINE cancer microarray database
Using the ONCOMINE cancer microarray database (www.oncomine.org) as
an integrated data-mining tool, we compared the gene expression profiles of
PARN and PLD2 in n=53 human tumor stoma samples contrasted against n=6
normal breast stroma samples. The Finak Breast dataset (Finak et al., 2008)
analyzed subtypes of tumor stroma corresponding to good- and poor-outcome
breast cancers from invasive breast cancer patients. The data link website for
the Finak Breast Dataset Summary can be found at https://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSE9014, which is maintained by the NCBI.
Dioleoyl-PA and NBD-PA incubation
‘Super-Stock’ 1 mM dioleoyl-PA was prepared with 1 mg of 1,2-dioleoyl-
sn-3-phosphate, or NBD-PA, in 1.4 ml of Super-Stock Buffer consisting of
50 mg of fatty acid-free BSA per 10 ml of 1× PBS, pH 7.2. Dioleoyl-PA is a
cell permeable form of phosphatidic acid (PA) (Lehman et al., 2007). This
Super-Stock dioleoyl-PA was then sonicated on ice 2×4 s each with a 4 s
pause in between sonications. ‘Intermediate 100 µM liposomes’ were then
made using 25 µl of the Super-Stock dioleoyl-PA and 225 µl of cell
starvation media (DMEM+0.1% bovine serum albumin), which were then
used to prepare the final concentration of 30 nM (unless otherwise indicated
by the figure legends) dioleoyl-PA used to incubate cells for the indicated
times in various figures.
Actinomycin D experiments
COS-7 cells were plated into 6-well plates and transfected with 1 µg PARN-
WTor left untreated. The day of the experiment, all cells were starved for 2 h
in cell starvation media. To test the effect of dioleoyl-PA, 300 nM dioleoyl-
PA in cell starvation media was added to relevant wells for 20 min or 4 h.
After the specified incubation time, the dioleoyl-PA solution was removed
and 50 nM actinomycin D in cell starvation media was added. After each
time point (0, 10, 30, 45, 60, and 90 min), the actinomycin D solution was
aspirated from the cells, wells were gently washed twice with 1× PBS,
trypsinized, and cells pelleted for use in qRT-PCR to measure PLD2 and
PARN gene expression. For each respective gene (PARN or PLD2), PARN
overexpressed plus dioleoyl-PA at time 0 was set to 100% and all other
samples were calculated and graphed relative to this point.
Cell transfection
Cellswere plated into 6-well plates in completemedia and allowed to grow12-
24 h before transfection. All overexpression transfections were accomplished
using 2 µg of PLD2 plasmid and/or 1 µg of PARN plasmid, 300 µl Opti-Mem
serum-freemedia, and 2 µl of Transit 2020 transfection reagent per 1 µgDNA.
For silencing, both the single and pooledPARNand PAN2 siRNAspurchased
were diluted with the manufacturer’s included nuclease free water to a stock
concentration of 50 µM. These siRNA solutions were then further diluted to
150 nM for use in all silencing experiments. Equal concentration of negative
control siRNA was used in the negative control siRNA transfections. The
siRNA reactions consisted of siRNA, 300 µl Opti-Mem serum-free media,
and 5 µl Dharmafect reagent. All reactions were incubated at room
temperature for 20 min before being added drop-wise to the corresponding
cells growing in complete media. Cells were then incubated at 37°C in an
incubator with a humidified atmosphere of 5% CO2 for 24 h. Media was
aspirated and fresh complete media added and cells allowed another 24 h of
growth in the incubator before harvesting.
SDS-PAGE/western blotting
COS-7 and MCF-7 cells were transfected as described previously in these
Materials and Methods with expression plasmids that are defined in the
figure legends. Cell media was aspirated from the plates and cells washed
twice gently with 1× PBS. Cells were then lifted from the plates by
incubation with the addition of 1 ml trypsin for no more than 5 min,
collected into 1.5 ml conical snap-cap tubes, and sedimented at 14000 g 4°C
for 1 min. The supernatant was aspirated and cell pellets were suspended in
special lysis buffer (SLB; 5 mM HEPES, 1 µM leupeptin, 768 nM
aprotinin, 100 µM sodium orthovanadate and 0.4% Triton X-100). After
sonication of the lysates, samples were resolved using SDS-PAGE and
transferred to a PVDF membrane, followed by immunoblot analysis with
anti-PARN (1:2000 dilution), anti-PLD2 (1:500 dilution), and anti-actin
(dilution 1:3000) antibodies and visualized using ECL reagents. Actin was
used as equal protein loading control.
Coomassie staining
Approximately, 100 ng of purified, recombinant PARN and PAN2 protein
were run on gels using standard SDS-PAGE protocol. The gel was then
rinsed three times for 5 min each in purified distilled water then incubated
overnight in 20 ml of GelCode Blue Safe Protein Stain (Thermo Scientific,
1860983) with gentle shaking. The gel was then destained using purified
distilled water rinses until the water remained colorless.
Gene expression measurement by quantitative real time PCR
(qRT-PCR)
Total RNAwas isolated from cells with the RNeasy minikit (Qiagen). RNA
concentrations were quantified using the NanoDrop ND-1000 UV/Vis
spectrophotometer and samples were normalized to 2 µg RNA. Reverse
transcription was performed with 2 µg RNA, 210 ng random hexamers,
500 µM dNTPs, 84 units RNaseOUT (Thermo Fisher), and 210 units of
Superscript II reverse transcriptase (Thermo Fisher) and incubated at 42°C
for 55 min. qPCR reactions were run with 100 ng total input RNA, 1 µl
(which contained 250 nM of the probe and 900 nM of the primers) of either
FAM-labeled PARN (TaqMan Gene Expression Assay Hs00377733_m1
4331182, Thermo Fisher) and or FAM-labeled PLD2 (TaqMan Gene
Expression Assay Hs01093219_m1 4351372) gene expression assay
multiplexed with the FAM-labeled housekeeping genes Actin (TaqMan
Gene Expression Assay Hs01060665_g1 4331182), GAPDH (TaqMan
Gene Expression Assay Hs02758991_g1 4331182), and TATA-binding
protein (TaqMan Gene Expression Assay Hs00427621_m1 4331182). qRT-
PCR conditions for the Stratagene Mx3000P were: 95°C for 3 min and then
40 cycles of the next 3 steps: 30 s 95°C, 1 min 60°C, and then 1 min 72°C.
The ‘cycle threshold’ Ct values were arbitrarily chosen from the linear part
of the PCR amplification curve where an increase in fluorescence can be
detected >10 s.e.m. above the background signal. ΔCt was calculated as:
ΔCt=mean PLD Ct–mean housekeeping Ct; and gene fold-expression, as
2-(ΔΔCt)=2-(experimental condition ΔCt – control ΔCt).
Immunofluorescence microscopy
COS-7 cells were seeded onto sterilized coverslips placed in the bottom of the
wells of 6-well plates and allowed 24 h for adherence. Cellswere incubated for
the times indicated in the figure legends in 30 nM fluorescent NBD-PA.
Media was aspirated off of cells and cells gently rinsed once with 1× PBS.
Cells were then fixed onto their cover slips using 4% paraformaldehyde for
10 min at room temperature. If only visualizing the NDB-PA, the nuclei were
then stained with DAPI and the coverslips mounted to microscope slides as
described further in the methods. If the cells were to be probed further with
antibodies against proteins, the cells were then permeabilized with 0.5%
Triton X-100 in PBS for 10 min at room temp and then incubated in 10% fetal
calf serum (FCS)–0.1% Triton X-100 in PBS for 1 h at room temp.
Endogenous expression of PARN was detected in samples using a 1:200
dilution of the corresponding IgG for 1 h at room temperature, followed by
washing three times in 1× PBS, and further room temperature incubation with
a 1:200 dilution of the appropriate TRITC-conjugated IgG secondary
antibody for 1 h. For PARN, donkey anti-goat secondary antibody was
used. After washing three times in 1× PBS, nuclei were stained using at a
1:2000 dilution of 4,6-diamidino-2-phenylindole (DAPI) in 1× PBS for 5 min
at room temp. Coverslips were washed again three times in 1× PBS and once
in distilled autoclaved water. Cover slips were then mounted onto clean glass
microscope slides using VectaShield mounting medium, and cells were
visualized using a Nikon 50 Eclipse epifluorescence microscope.
Quantification of co-localization of PARN with PA
COS-7 cells were incubated for 30 min in 30 nM fluorescent PA
(1-oleoyl-2-(6-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]hexanoyl)-sn-glycero-
3-phosphate, NBD-PA) and taken for immunofluorescence microscopy
using TRITC-conjugated antibodies against PARN and DAPI. Photos were
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taken from separate fields under green (excitation=490 nm;
emission=525 nm, FITC) and red (excitation=557 nm; emission=576 nm,
TRITC) filters. Localization of the NBD-PA is in green fluorescence,
localization of PARN is in red fluorescence and DAPI in deep blue
fluorescence. Images were merged in Adobe Photoshop that rendered
yellow spots associated with different sized intracellular vesicles. PA/PARN
co-localization was represented by the presence of yellow (defined as
550 nm wavelength) in large (>0.5 mm vesicles), punctae (<0.5 mm
vesicles) or diffuse distributions. This classification of vesicles is in
accordance with a previous publication from our lab (Henkels et al., 2016).
For quantification, relative fluorescence units (RFU) were measured from
the image fields. The ratio for yellow (550 nm) was calculated with a method
modified from (Comeau et al., 2006), as ratio (RFUYellow-RFURed)/total
fluorescence in the field of observation and ratio (RFUYellow-RFUGreen)/total
fluorescence in the field of observation. Co-localization occurs when the
two ratio values are within 15% of each other and each of the ratios is at least
70% of maximum values.
PLD and PARN activity assay
Cell lysates were processed for PLD activity in PC8 liposomes and [3H]n-
butanol beginning with the addition of the following reagents (final
concentrations): 3.5 mM PC8 phospholipid, 45 mM HEPES (pH 7.8) and
1.0µCi [3H]n-butanol in a liposome form, to accomplish the
transphosphatidylation reaction of PLD, and were incubated for 20 min at
30°C with continuous shaking. Reactions were stopped with the addition of
0.3 ml ice-cold chloroform/methanol (1:2), and lipids were isolated and
resolved by thin layer chromatography. The amount of [3H]-phospho-
butanol ([3H]-PBut) that co-migrated with PBut standards (Rf=0.45–0.50)
was measured by scintillation spectrometry.
For PARN activity, the in vitro assay was based on (Wilson and
Treisman, 1988b; Shyu et al., 1991) with some modifications. Cell lysates
overexpressing PARN or several other plasmids, as indicated in the
legends to the figures, were subjected to deadenylation of a radiolabeled
A15 RNA substrate. Positive controls were recombinant purified
PARN and negative controls were just A15 substrate. Reactions products
were subjected to autoradiography. Radiolabeled A15 RNA substrate
was deadenylated by recombinant PARN or by COS-7 cell lysates in a
reaction assay buffer contained protease and phosphatase inhibitors.
Deadenylation is evidenced by a greater mobility of radiolabeled spots,
the appearance of smears versus the negative control of A15 alone, and a
lighter signal. This was quantified with a formula: PARN activity =
migrationðmmÞ of A10
A15
 area of band 1
density of band
.
Statistical analysis
Data presented in the figures as bars are means+s.e.m. (standard deviation/
n1/2, where n is the sample size). Experiments were performed in technical
triplicates (for qPCR assays) or technical duplicates (for PARN and PLD
activity assays) for n=5 independent experiments. The difference between
means was assessed by the single factor analysis of variance (ANOVA) test,
calculated using SigmaPlot version 10 (Systat Software Inc., San Jose, CA).
Probability of P<0.05 indicates a significant difference. In the figures, the
(*) symbols above bars denote statistically significant (P<0.05) ANOVA
increases between samples and controls. The (#) symbols above bars denote
statistically significant (P<0.05) ANOVA decreases between samples and
controls.
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Mazan-Mamczarz, K., Galban, S., López de Silanes, I., Martindale, J. L., Atasoy,
U., Keene, J. D. and Gorospe, M. (2003). RNA-binding protein HuR enhances
p53 translation in response to ultraviolet light irradiation. Proc. Natl. Acad. Sci.
USA 100, 8354-8359.
Mian, I. S. (1997). Comparative sequence analysis of ribonucleases HII, III, II PH
and D. Nucleic Acids Res. 25, 3187-3195.
Mitchell, P. and Tollervey, D. (2000). mRNA stability in eukaryotes. Curr. Opin.
Genet. Dev. 10, 193-198.
Moraes, K. C. M., Wilusz, C. J. and Wilusz, J. (2006). CUG-BP binds to RNA
substrates and recruits PARN deadenylase. RNA 12, 1084-1091.
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